Project

BMS_IM101-863

Completed - recruitment closed ยท 2022 until 2025

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed - recruitment closed
Start Date
2022
End Date
2025
Financing
Others
Brief description/objective

A Phase 3, Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate